The case for & against
Bull & Bear analysis
Waters Corporation (NYSE: WAT) is a leading player in the analytical instrumentation sector, recognized for providing comprehensive solutions in chromatography and mass spectrometry. The company operates primarily within the life sciences and pharmaceutical markets, offering instruments and software that cater to increasingly sophisticated analytical challenges. Recently, Waters has made a significant strategic move by acquiring Becton Dickinson's biosciences and diagnostic solutions business, positioning itself to leverage new growth opportunities across various high-demand sectors, particularly in diagnostics and drug development.
Bull says
- ↑Q1 revenue $1.267B (+13% YoY) and adjusted EPS $2.70 (+20%), exceeding guidance
- ↑BD acquisition synergy target of $50M, with initial cost savings under way
- ↑Gross margin 54.7% and operating margin 23.6%, ~200bps above projections
- ↑Alliance IS sales surged 300%, reflecting strong product innovation and market share gains
- ↑Strong profitability metrics and positive analyst sentiment suggest attractive valuation
- ↑Rising biopharma and diagnostics demand to support sustained growth
Bear says
- ↓Integration challenges from BD acquisition risk delaying targeted synergies
- ↓Academic and government funding declines may curb equipment orders
- ↓Inflation and tariffs pressure costs, potentially compressing profit margins
- ↓Limited institutional ownership reflects reduced confidence in growth prospects
- ↓Weak momentum factors and elevated short interest could cap stock upside
- ↓Regulatory uncertainties in PFAS testing may impact near-term revenues
Investment themes with WAT
Companies with strong fundamentals and stability
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- In the first quarter of 2026, we continue to deliver industry-leading growth. We delivered reported revenue of 1.267 billion, which was ahead of expectations.
- Organic revenue was 747 million, growing 13% as reported, and 11% in constant currency, which was 200 basis points, above the high end of our guidance range.
- Our newly acquired businesses delivered $520 million of revenue during our period of ownership, $40 million above guidance, and representing 7% estimated as reported growth versus the comparable prior year stop period.
Bear points
- On a gap basis, we reported a diluted loss per share of $0.87, reflecting acquisition-related purchase accounting charges, including amortization of acquired intangibles and inventory step-up, as is typical following a transaction of this scale.
- Free cash flow for the quarter was 42 million outlay impacted by deal-related transaction costs and the timing of net cash settlement with BD.
- Excluding these impacts, growth was approximately 3% for the full quarter.